Mr. O’Day joined Gilead in 2019 to lead the biopharmaceutical company, which has more than 11,000 employees around the world.
Prior to Gilead, Mr. O’Day served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia. During his time at Roche, Mr. O’Day demonstrated vision and leadership, helping to engineer the acquisitions of Flatiron Health and Foundation Medicine in 2018. He served as a member of the company’s Corporate Executive Committee, as well as on a number of public and private boards, including Genentech.
Mr. O’Day holds a bachelor’s degree in biology from Georgetown University and an MBA from Columbia University in New York.
Gilead Sciences, Inc., commonly known as Gilead Sciences or Gilead (also styled GILEAD) /ˈɡɪliəd/, is an American biotechnologycompany that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Headquartered and founded in Foster City, California, Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
